HSPA5 and triple-negative breast carcinoma: Importantly, knockdown of GRP78 in shRNA-treated BT-549 cells resulted in the significant decrease in PD-L1 on their surface [140]; this means that enforced inhibiting the GRP78 expression in triple negative breast cancer cells can render them more vulnerable to attacks of cytolytic T-cells.